morphine sulfate injection, USP VIAL Contraindications

()

4 CONTRAINDICATIONS

Preservative-free morphine sulfate injection is contraindicated in patients with:

Significant respiratory depression [see Warnings and Precautions (5.3)]
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.9)]
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions (5.10), Drug Interactions (7)]
Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.14)]
Hypersensitivity to morphine (e.g., anaphylaxis) [see Adverse Reactions (6)]

Neuraxial administration of preservative-free morphine sulfate injection is contraindicated in patients with:

Infection at the injection microinfusion site [see Warnings and Precautions (5.1)]
Concomitant anticoagulant therapy [see Warnings and Precautions (5.1)]
Uncontrolled bleeding diathesis [see Warnings and Precautions (5.1)]
The presence of any other concomitant therapy or medical condition which would render epidural or intrathecal administration of medication especially hazardous.

Find morphine sulfate injection, USP VIAL medical information:

Find morphine sulfate injection, USP VIAL medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

morphine sulfate injection, USP VIAL Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Contraindications

4 CONTRAINDICATIONS

Preservative-free morphine sulfate injection is contraindicated in patients with:

Significant respiratory depression [see Warnings and Precautions (5.3)]
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.9)]
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions (5.10), Drug Interactions (7)]
Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.14)]
Hypersensitivity to morphine (e.g., anaphylaxis) [see Adverse Reactions (6)]

Neuraxial administration of preservative-free morphine sulfate injection is contraindicated in patients with:

Infection at the injection microinfusion site [see Warnings and Precautions (5.1)]
Concomitant anticoagulant therapy [see Warnings and Precautions (5.1)]
Uncontrolled bleeding diathesis [see Warnings and Precautions (5.1)]
The presence of any other concomitant therapy or medical condition which would render epidural or intrathecal administration of medication especially hazardous.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.